Kezar stock falls 11% after board rejects Concentra offer (update)
Kezar (KZR) stock fell 11% after the company's board rejected an unsolicited takeover offer from Concentra Biosciences and ...
FierceBiotech6d
Kezar rejects Concentra bid that 'substantially undervalues' the biotech
Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra Biosciences. Concentra’s parent company Tang Capital Partners has a track ...
Business Insider6d
Kezar Life Rejects Proposal From Concentra; Board Adopts Limited Duration Stockholder Rights Plan
(RTTNews) - Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to acquire all of the outstanding shares of common ...
Benzinga.com5d
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
Earlier on Thursday, Kezar Life Sciences rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences for cash consideration of $1.10 per share, plus a contingent ...
Business Insider3d
Insider Today: America's billionaire hub
Happy Saturday! Gen Z is redefining yet another term, and this time, it's "lavender marriage." A phrase once reserved for the LGBTQ+ community is now being used to describe young people who are ...
Wall Street Journal5d
Concentra Group Holdings Parent Inc.
1 Day CON 0.52% DJIA 0.09% S&P Mid Cap 400 0.01% Health Care/Life Sciences 0.22% ...
Wall Street Journal6d
Concentra Group Holdings Parent Inc.
1 Day CON -2.54% DJIA 0.37% S&P Mid Cap 400 0.15% Health Care/Life Sciences -0.15% ...